Nyken

Nyken was a Netherlands-based biopharmaceutical company focused on developing small-molecule activators of heat shock factor 1 to treat proteostasis-related diseases. Its programs were aimed at conditions including atrial fibrillation, acute kidney injury, and certain central nervous system pathologies. Available third-party sources indicate the company built an intellectual property portfolio around heat-shock response modulation and advanced several named preclinical assets. Nyken appears to have been acquired or otherwise absorbed through the transfer of its intellectual property and patent portfolio to Chaperone Pharma. The company is best characterized as an early-stage platform biotech centered on HSF1 and heat-shock protein induction.